Bayer

Clear out clearnance rubbish scrap heap
Biotech

Bayer bails on Vividion tumor drug in early-stage clear-out

Bayer has cleared out four cancer candidates from its early-stage pipeline, including a STAT3 inhibitor acquired as part of its buyout of Vividion.
James Waldron Nov 12, 2025 8:10am
reshuffle pipeline target reorganize shift change

ESMO: Exelixis' TKI reduces risk of death by 20%

Oct 20, 2025 2:30am
Kumquats

Bayer picks Kumquat for $1.3B KRAS collaboration

Aug 12, 2025 6:29am
end of the road road block shut down closed blocked

Bayer-allied NextRNA Therapeutics winds down operations

Aug 11, 2025 2:30pm
team layoffs workforce

Bayer-owned BlueRock lays off 50 employees, shuts Cambridge labs

Jun 25, 2025 7:46am
Glowing puzzle piece fitting into puzzle

Vividion secures clinical-stage WRN inhibitor from Roche

Jun 4, 2025 9:21am